<DOC>
	<DOCNO>NCT00697567</DOCNO>
	<brief_summary>The purpose phase IIa study healthy HSV seropositive HSV seronegative adult evaluate immunogenicity , reactogenicity safety herpes simplex ( gD ) candidate vaccine without adjuvant administer accord 0 , 1 , 6 month schedule .</brief_summary>
	<brief_title>Evaluation Immunogenicity , Reactogenicity Safety Herpes Simplex ( gD ) Candidate Vaccine With/Without Adjuvant</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Between 18 40 year age Written inform consent Female volunteer must use contraceptive avoid become pregnant duration study . Good clinical condition evidence history take physical examination History persistent hepatic , renal , cardiac respiratory disease . Clinical sign acute illness time entry study . Seropositive antibody human immunodeficiency virus ( HIV ) . Pregnancy , lactation . Treatment corticosteroid immunomodulating drug . Simultaneous participation another clinical trial . Any previous history allergy . Any concomitant vaccination administration immunoglobulin study period . Any abnormal laboratory value among test perform screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Herpes simplex</keyword>
	<keyword>Herpes simplex vaccine</keyword>
</DOC>